Trial Profile
A Phase I/II Study of Sorafenib (BAY 43-9006) in Combination With Low Dose ARA-C (Cytarabine) in Elderly Patients With AML [acute myeloid leukaemia] or High-Risk MDS [myelodysplastic syndrome]
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 08 Aug 2023
Price :
$35
*
At a glance
- Drugs Cytarabine (Primary) ; Sorafenib (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions; Therapeutic Use
- 21 Sep 2013 Additional lead trial centre identified as reported by ClinicalTrials.gov.
- 12 Dec 2009 Status changed from recruiting to completed as reported by National Cancer Institute of Canada.
- 28 Oct 2008 Updated from National Cancer Institute of Canada site.